Type 1 diabetes is an autoimmune disorder characterized by beta cell destruction resulting in
insulinopenia. Currently it is being treated with insulin. Dipeptidylpeptidase inhibitors
(DPP4 inhibitors e.g. linagliptin & sitagliptin) has been used for type 2 diabetes mellitus
(T2DM) traditionally. Previous studies has shown that it is also effective in type 1 diabetes
mellitus (T1DM), but the mechanism of action not well understood. This study will evaluate
possible mechanism of action of linagliptin in T1DM patients.
Phase:
N/A
Details
Lead Sponsor:
Postgraduate Institute of Medical Education and Research